for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Breakingviews

Breakingviews: AstraZeneca's struggling defence

Posted

The UK pharma group fought Pfizer's $120 billion bid by promising growth. But its defence has been aided most by U.S. curbs on tax-driven M&A, says Reuters Breakingviews.

Breakingviews

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up